The Technical Analyst
Nevro Corp [NVRO]
Exchange: NYSE Sector: Healthcare Industry: Medical Devices
Nevro Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.66% $10.43
America/New_York / 9 mai 2024 @ 15:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 379.63 mill |
| EPS: | -2.28 |
| P/E: | -4.57 |
| Earnings Date: | Jul 30, 2024 |
| SharesOutstanding: | 36.40 mill |
| Avg Daily Volume: | 0.505 mill |
| RATING 2024-05-09 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.57 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -4.57 | industry: PE -41.13 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.79 - 11.11 ( +/- 6.28%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-24 | Thornal Kevin R | Sell | 24 233 | Common Stock |
| 2024-04-11 | Grossman D Keith | Sell | 3 986 | Common Stock |
| 2024-04-04 | Rashid Kashif | Sell | 479 | Common Stock |
| 2024-03-31 | Kosaraju Sridhar | Buy | 1 090 | Common Stock |
| 2024-03-31 | Demane Michael F | Buy | 1 817 | Common Stock |
| INSIDER POWER |
|---|
| 60.43 |
| Last 97 transactions |
| Buy: 980 834 | Sell: 269 822 |
Forecast:
16:00 - $10.43
Live Trading Signals (every 1 min)
Forecast
1: 15:32 - $10.44
Forecast 2: 16:00 - $10.43
Forecast 3: 16:00 - $10.43
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.43 (2.66% ) |
| Volume | 0.383 mill |
| Avg. Vol. | 0.505 mill |
| % of Avg. Vol | 75.81 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NVRO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NVRO
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Latest Press Releases
2024-05-07 16:05:00 - Press Release
Nevro Reports First-quarter 2024 Financial Results
Announces additional restructuring steps to advance strategy and accelerate profitability raises adjusted ebitda guidance and reaffirms revenue guidance for full-year 2024 promotes christofer christoforou to chief operating officer redwood city, calif. , may 7, 2024 /prnewswire/ -- nevro corp. (nyse: nvro), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results.
2024-04-17 08:30:00 - Press Release
Nevro To Report First-quarter 2024 Financial Results And Host Earnings Conference Call On May 7, 2024
Redwood city, calif. , april 17, 2024 /prnewswire/ -- nevro corp. (nyse: nvro), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on tuesday, may 7, 2024.
2024-02-28 16:10:00 - Press Release
Nevro Receives Fda 510(k) Clearance To Use Si Fixation System Without Need To Include Lateral Screw
Nevro1™ proven to immediately transfix sacroiliac (si) joint to allow for long-term si joint fusion redwood city, calif. , feb. 28, 2024 /prnewswire/ -- nevro corp. (nyse: nvro), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the u.s. food and drug administration (fda) cleared its sacroiliac joint fusion device, which will be marketed as nevro1, without the need to include the screw ("nevrofix™").
2024-02-21 16:06:00 - Press Release
Nevro Enters Into Cooperation Agreement With Engaged Capital
Appoints kirt p. karros to board of directors redwood city, calif.
2024-02-21 16:05:00 - Press Release
Nevro Reports Fourth-quarter And Full-year 2023 Financial Results
Provides full-year and first-quarter 2024 guidance redwood city, calif. , feb. 21, 2024 /prnewswire/ --nevro corp. (nyse: nvro), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results.
Latest News
2024-05-08 13:16:22 - Zacks Investment Research
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
2024-05-08 02:01:01 - Seeking Alpha
Nevro Corp. (NVRO) Q1 2024 Earnings Call Transcript
Nevro Corp. (NYSE:NVRO ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and President Rod MacLeod - Chief Financial Officer Conference Call Participants Nathan Treybeck - Wells Fargo Anthony Petrone - Mizuho Carolyn Huszagh - Bank of America Justin Lin - William Blair Bradley Bowers - Mizuho Securities Operator Good afternoon. My name is Audra, and I will be your conference operator today.
2024-05-07 18:31:09 - Zacks Investment Research
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.98 per share a year ago.
2024-03-21 13:36:03 - Zacks Investment Research
Here's Why You Should Retain Nevro (NVRO) Stock for Now
2024-02-29 08:31:13 - Zacks Investment Research
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
2024-02-22 18:21:23 - The Motley Fool
Why Nevro Stock Lagged the Market on Thursday
Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.
2024-02-22 11:51:04 - Zacks Investment Research
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
2024-02-21 23:02:06 - Seeking Alpha
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
2024-02-21 18:21:08 - Zacks Investment Research
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.54 per share a year ago.
2024-01-19 11:51:05 - Zacks Investment Research
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.